Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Business Segments — Income Tax Expense Benefit

Similar metrics at other companies

Cherry Hill Mortgage Investment logo
CHMIAll Other Segments — Income Tax Expense Benefit
$0
Bank of the James Financial Group logo
BOTJAll Other Segments — Income Tax Expense Benefit
-$51.5K-5.6%
UFP Industries, Inc. logo
UFPIAll Other Segments — Income Tax Expense Benefit
$1.66M+297%
Unitil logo
UTLAll Other Segments — Income Tax Expense Benefit
-$200K+66.7%
C&F Financial logo
CFFIAll Other Segments — Income Tax Expense Benefit
-$360K-15.4%
OGE Energy logo
OGEAll Other Segments — Income Tax Expense Benefit
-$2.3M-76.9%

Other financials

Income statement

See full
Revenue$401.3M-34.3%
Operating income$13.3M-88.5%
Net income-$4.9M-102%
EPS (diluted)-$0.05-103%

Balance sheet

See full
Cash & equivalents$571.1M+11.9%
Total debt$198.2M-7.6%
Total equity$1.5B+8.8%
Total assets$3.2B-13.4%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$555.0K-98.3%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.77B+10.9%
Enterprise value$1.4B+7.5%
P/S0.9×

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin-6.9%
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-9.3%+2,662pp
Debt / equity0.1×0.0×
Current ratio4.4×+1.5×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:01 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335003
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Loss (gain) on strategic investments448(36,721)2,16054,007
Interest expense21,5085,22843,2219,731
Interest income(6,207)(5,254)(12,567)(15,444)
Income tax expense (benefit)3,141(43,254)15,35620,736
Depreciation and amortization expense10,40910,84021,00320,818
Stock-based compensation expense24,47237,02553,87178,453
Litigation contingency charge39,00039,000
Segment net (loss) income$(4,890)$196,892$326,069$(250,616)

Item 1. Financial Statements

FAQ

What is Sarepta Therapeutics, Inc.'s business segments — income tax expense benefit?
Sarepta Therapeutics, Inc. (SRPT) reported business segments — income tax expense benefit of $3.14M in Q2 2026.
How has Sarepta Therapeutics, Inc.'s business segments — income tax expense benefit changed year-over-year?
Sarepta Therapeutics, Inc.'s business segments — income tax expense benefit increased by 107.3% year-over-year, from -$43.25M to $3.14M.
What does business segments — income tax expense benefit mean?
The provision for income taxes allocated to the segment based on its taxable earnings or jurisdictional requirements. This metric captures the tax impact on the segment's bottom-line performance. It is essential for understanding the segment's net contribution after accounting for fiscal obligations.

Ask your AI about Sarepta Therapeutics, Inc.'s business segments — income tax expense benefit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude